» Articles » PMID: 29953464

Risk Factors for Mortality in Patients with Acute Leukemia and Bloodstream Infections in the Era of Multiresistance

Abstract

Objectives: We assess the epidemiology and risk factors for mortality of bloodstream infection (BSI) in patients with acute leukemia (AL).

Methods: Prospectively collected data of a cohort study from July 2004 to February 2016. Multivariate analyses were performed.

Results: 589 episodes of BSI were documented in 357 AL patients, 55% caused by gram-positive bacteria (coagulase-negative staphylococci 35.7%, Enterococcus spp 10.8%) and 43.5% by gram-negative bacteria (E. coli 21%, PA 12%). We identified 110 (18.7%) multidrug-resistant (MDR) microorganisms, especially MDR-Pseudomonas aeruginosa (7%) and extended-spectrum beta-lactamase producing Enterobacteriaceae (7%). The 30-day mortality was 14.8%. Age (OR 3.1; 95% CI 1.7-5.7); chronic lung disease (4.8; 1.1-21.8); fatal prognosis according to McCabe index (13.9; 6.4-30.3); shock (3.8; 1.9-7.7); pulmonary infection (3.6; 1.3-9.9); and MDR-PA infections with inappropriate treatment (12.8; 4.1-40.5) were related to mortality. MDR-PA BSI was associated to prior antipseudomonal cephalosporin use (9.31; 4.38-19.79); current use of betalactams (2.01; 1.01-4.3); shock (2.63; 1.03-6.7) and pulmonary source of infection (9.6; 3.4-27.21).

Conclusions: MDR organisms were commonly isolated in BSI in AL. Inappropriate empiric antibiotic treatment for MDR-PA is the primary factor related to mortality that can be changed. New treatment strategies to improve the coverage of MDR-PA BSI should be considered in those patients with risk factors for this infection.

Citing Articles

2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies.

Sandherr M, Stemler J, Schalk E, Hattenhauer T, Hentrich M, Hertenstein B Lancet Reg Health Eur. 2025; 51:101214.

PMID: 39973942 PMC: 11836497. DOI: 10.1016/j.lanepe.2025.101214.


Development and Validation of a Machine Learning Model for the Prediction of Bloodstream Infections in Patients with Hematological Malignancies and Febrile Neutropenia.

Gallardo-Pizarro A, Teijon-Lumbreras C, Monzo-Gallo P, Aiello T, Chumbita M, Peyrony O Antibiotics (Basel). 2025; 14(1).

PMID: 39858299 PMC: 11760484. DOI: 10.3390/antibiotics14010013.


Metagenomics: a new frontier for routine pathology testing of gastrointestinal pathogens.

Angel N, Sullivan M, Alsheikh-Hussain A, Fang L, MacDonald S, Pribyl A Gut Pathog. 2025; 17(1):4.

PMID: 39827146 PMC: 11742996. DOI: 10.1186/s13099-024-00673-1.


Bloodstream infections in pediatric hematology/oncology patients: a single-center study in Wuhan.

Murshed I, Zhao L, Zhang W, Yin Y, Li Y, Peng Y Front Cell Infect Microbiol. 2024; 14:1480952.

PMID: 39698316 PMC: 11652520. DOI: 10.3389/fcimb.2024.1480952.


[A single-center analysis of pathogenic bacteria distribution and drug resistance in bacterial bloodstream infections among patients with hematological diseases].

Che M, Wang C, Liu H, Kong H, Li L, Song J Zhonghua Xue Ye Xue Za Zhi. 2024; 45(10):937-943.

PMID: 39622758 PMC: 11579750. DOI: 10.3760/cma.j.cn121090-20240603-00201.


References
1.
Tumbarello M, Spanu T, Caira M, Trecarichi E, Laurenti L, Montuori E . Factors associated with mortality in bacteremic patients with hematologic malignancies. Diagn Microbiol Infect Dis. 2009; 64(3):320-6. DOI: 10.1016/j.diagmicrobio.2009.02.008. View

2.
Madani T . Clinical infections and bloodstream isolates associated with fever in patients undergoing chemotherapy for acute myeloid leukemia. Infection. 2001; 28(6):367-73. DOI: 10.1007/s150100070007. View

3.
Trecarichi E, Pagano L, Candoni A, Pastore D, Cattaneo C, Fanci R . Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clin Microbiol Infect. 2015; 21(4):337-43. DOI: 10.1016/j.cmi.2014.11.022. View

4.
Arias C, Murray B . The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol. 2012; 10(4):266-78. PMC: 3621121. DOI: 10.1038/nrmicro2761. View

5.
Ortega M, Soriano A, Marco F, Almela M, Martinez J, Morata L . Risk factors for the isolation of a third generation cephalosporin resistant strain in patients with community-acquired Enterobacteriaceae bacteraemia. J Infect. 2015; 72(2):268-71. DOI: 10.1016/j.jinf.2015.11.006. View